696 related articles for article (PubMed ID: 14756010)
1. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
4. [Cholestatic liver diseases].
Thimme R; Opitz OG; Blum HE; Kreisel W
Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
[TBL] [Abstract][Full Text] [Related]
5. [Cholestasis: therapeutic options].
Beuers U; Oswald M
Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
[TBL] [Abstract][Full Text] [Related]
6. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
7. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
8. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
9. Management of autoimmune and cholestatic liver disorders.
Krok KL; Munoz SJ
Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
[TBL] [Abstract][Full Text] [Related]
10. [Primary biliary cirrhosis: therapeutic options].
Abenavoli L
Recenti Prog Med; 2009 Sep; 100(9):417-23. PubMed ID: 19886235
[TBL] [Abstract][Full Text] [Related]
11. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
13. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
14. [No complaints, but constantly elevated cholestatic serum liver tests].
Kherbèche H
Praxis (Bern 1994); 2011 Jul; 100(14):865-7. PubMed ID: 21732301
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of overlap syndromes.
Bunchorntavakul C; Reddy KR
Clin Liver Dis; 2015 Feb; 19(1):81-97. PubMed ID: 25454298
[TBL] [Abstract][Full Text] [Related]
16. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
17. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
18. [Primary biliary cirrhosis (PBC)].
Rautiainen H
Duodecim; 2012; 128(15):1550-9. PubMed ID: 22970606
[TBL] [Abstract][Full Text] [Related]
19. Primary sclerosing cholangitis.
Geonzon-Gonzales MR
Gastroenterol Nurs; 2007; 30(2):102-5; quiz 105-7. PubMed ID: 17440311
[TBL] [Abstract][Full Text] [Related]
20. Transplantation trends in primary biliary cirrhosis.
Lee J; Belanger A; Doucette JT; Stanca C; Friedman S; Bach N
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1313-5. PubMed ID: 17900996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
